{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336751","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2026-08-06T11:30:08+00:00","discovered_at":"2026-08-06T11:35:00.319643+00:00","generated_at":"2026-08-06T11:35:58.806461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nuvation Bio Q2 2026 revenue $31.7M, IBTROZI net product revenue $23.2M; net loss $62.8M","bullets":["Total revenue $31.7M, including $23.2M net product revenue from IBTROZI (ROS1 TKI) and $8.5M collaboration/license revenue.","Net loss $62.8M ($0.18/share) vs $59.0M ($0.17/share) in Q2 2025; R&D spend $30.7M, SG&A $42.6M.","Cash, equivalents, and marketable securities $661.0M as of June 30, 2026; additional $36.5M from July convertible notes overallotment.","IBTROZI most prescribed ROS1 TKI in 2026; ~85% of ~160 new patient starts were TKI-naïve (30% QoQ growth).","Safusidenib Phase 2 shows 51.9% ORR, median PFS not reached at 38.8 months; pivotal Phase 3 and Phase 2 studies initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336751","json":"https://secwatch.observer/filing/0001193125-26-336751.json","markdown":"https://secwatch.observer/filing/0001193125-26-336751.md","text":"https://secwatch.observer/filing/0001193125-26-336751.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/0001193125-26-336751-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526336751/d261840d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:35:58.806461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}